Recent articles
Invitae Delivers Strong Growth in First Quarter, Readies Investment Surge
Management thinks the company is on track for $500 million in revenue in 2020, but achieving that will require considerable capital investment.
Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today
The pharma announced first-quarter 2019 operating results.
Here's Why Puma Biotechnology Fell 17.2% in April
Investors reacted with dismay over the terms of a license agreement.
Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today
The pharma company announced first-quarter 2019 operating results.
Should Investors Worry Over a Sluggish First Quarter for Vanda Pharmaceuticals?
Revenue from the company's two drug products decreased 10% from the fourth quarter of 2018.
Here's Why Sangamo Therapeutics Fell as Much as 13.6% Today
The biopharma announced first-quarter 2019 operating results.
Codexis Bags Novartis as Software Customer, Stays Course in First Quarter
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
Here's Why Zogenix Dropped 29.1% in April
The pharma company got a rejection letter from the U.S. Food and Drug Administration.
Here's Why Gentex Stock Rose 11.4% in April
The auto parts supplier reported first-quarter 2019 earnings.
Here's Why Invitae Got Crushed Today
The genetic testing leader and Wall Street weren't on the same page for first-quarter 2019 revenue.
Small-Cap Stocks to Watch in May
These two companies are set to announce important business updates this month.
What to Watch When Franco-Nevada Reports Q1 2019 Earnings
The diversified streaming company expects to see a surge in production. Can it erase the pain of a sour performance in 2018?
Here's Why TherapeuticsMD Fell as Much as 17.6% Today
The women's health company reported first-quarter 2019 operating results.
Here's Why Lannett Company Stock Is Collapsing Today
Quarterly operating results were pretty good, but the business disclosed that it may face a lawsuit along with other makers of generic drugs.
3 Top Chinese Stocks to Watch in May
The Chinese market has been a source of incredible growth for investors in recent years. Will ongoing economic turmoil challenge that?
What to Watch When Albemarle Reports Q1 Earnings
The world's largest lithium producer could provide important updates about its long-term strategy.
Fluidigm Delivers Growth Where It Matters Most in Q1 2019
The decision to retire $150 million in convertible debt caught the market off guard, but the business made progress on its long-term goals.
Renewable Energy Group Couldn't Outrun Weak Margins in Q1 2019
The business struggled with expected pricing challenges, but made progress on several long-term initiatives.
What to Watch When Green Plains Reports Q1 Earnings
The ethanol producer needs to begin showing tangible signs of progress from its recent strategy shift.
Here's Why Fluidigm Shares Fell as Much as 14.4% Today
The laboratory equipment manufacturer announced first-quarter 2019 operating results and a significant transaction.